{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T06:30:23Z","timestamp":1781332223719,"version":"3.54.1"},"reference-count":261,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.autrev.2026.104058","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:10:04Z","timestamp":1776323404000},"page":"104058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innate immunity and biomarkers of multiple sclerosis relapse versus remission"],"prefix":"10.1016","volume":"25","author":[{"given":"Meltem","family":"Karadeniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robb","family":"Wesselingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmakrishnan C.","family":"Jayakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Van Der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mastura","family":"Monif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.autrev.2026.104058_bb0005","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2026.104058_bb0010","series-title":"Recent Understanding and Potential Application Perspectives. Neurology Research International","first-page":"2022","article-title":"Correlation between the Neutrophil-to-Lymphocyte Ratio and Multiple Sclerosis","author":"Zhou","year":"2022"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb0015","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095162","article-title":"Proteomics in multiple sclerosis: the perspective of the clinician","volume":"23","author":"Sandi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104058_bb0025","series-title":"The multiple sclerosis international federation","year":"2020"},{"issue":"22","key":"10.1016\/j.autrev.2026.104058_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005612","article-title":"Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women","volume":"90","author":"Koch-Henriksen","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0035","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000713","article-title":"High incidence and prevalence of MS in M\u00f8re and Romsdal County, Norway, 1950\u20132018","volume":"7","author":"Willumsen","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235562","article-title":"Age and sex-adjusted incidence and yearly prevalence of multiple sclerosis (MS) in Mazandaran province, Iran: an 11-years study","volume":"15","author":"Cheraghmakani","year":"2020","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.autrev.2026.104058_bb0045","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/1352458516671819","article-title":"Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study","volume":"23","author":"Ribbons","year":"2017","journal-title":"Mult Scler J"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104058_bb0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000493857","article-title":"Multiple sclerosis incidence and prevalence trends in the province of Padua, Northeast Italy, 1965\u20132018","volume":"52","author":"Grassivaro","year":"2019","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.autrev.2026.104058_bb0055","series-title":"Health economic impact of multiple sclerosis in Australia in 2021: An interim update of prevalence, costs and cost of illness from 2017 to 2021","author":"Campbell","year":"2023"},{"key":"10.1016\/j.autrev.2026.104058_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241237853","article-title":"Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events","volume":"17","author":"Thr\u00e4nhardt","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029819","article-title":"Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations","volume":"7","author":"Alcina","year":"2012","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb0070","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/eji.202149179","article-title":"HLA-DRB1*15:01 is a co-receptor for Epstein-Barr virus, linking genetic and environmental risk factors for multiple sclerosis","volume":"51","author":"Menegatti","year":"2021","journal-title":"Eur J Immunol"},{"issue":"6578","key":"10.1016\/j.autrev.2026.104058_bb0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/1352458506073501","article-title":"Smoking is a risk factor for multiple sclerosis: a metanalysis","volume":"13","author":"Hawkes","year":"2007","journal-title":"Mult Scler"},{"issue":"21","key":"10.1016\/j.autrev.2026.104058_bb0085","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1212\/WNL.0b013e3182752ea8","article-title":"Vitamin D as a protective factor in multiple sclerosis","volume":"79","author":"Salzer","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"issue":"20","key":"10.1016\/j.autrev.2026.104058_bb0095","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1212\/WNL.0b013e3181c1e44f","article-title":"Impact of multiple sclerosis relapses on progression diminishes with time","volume":"73","author":"Tremlett","year":"2009","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb0100","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104058_bb0105","unstructured":"Prosperini L, Ruggieri S, Haggiag S, Tortorella C, Gasperini C. Disability patterns in multiple sclerosis: a meta-analysis on RAW and PIRA in the real-world context. Multiple Sclerosis Journal 0(0):13524585241266180."},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0110","article-title":"Assessment and treatment strategies for a multiple sclerosis relapse","volume":"5","author":"Wang","year":"2018","journal-title":"J Immunol Clin Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0115","first-page":"1","article-title":"Multiple sclerosis: pathogenesis, symptoms","volume":"19","author":"Ghasemi","year":"2017","journal-title":"Diagnoses and Cell-Based Therapy Cell J"},{"key":"10.1016\/j.autrev.2026.104058_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.31128\/AJGP-07-21-6103","article-title":"Multiple sclerosis: diagnosis, disease-modifying therapy and prognosis","volume":"51","author":"Travers","year":"2022","journal-title":"Aust J Gen Practitioners"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.30773\/pi.2019.0106","article-title":"Neuropsychiatric symptoms of multiple sclerosis: state of the art","volume":"16","author":"Silveira","year":"2019","journal-title":"Psychiatry Investig"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0130","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1352458516643392","article-title":"Contribution of different relapse phenotypes to disability in multiple sclerosis","volume":"23","author":"Stewart","year":"2017","journal-title":"Mult Scler J"},{"issue":"0","key":"10.1016\/j.autrev.2026.104058_bb0135","article-title":"revision of the McDonald diagnostic criteria for MS: Substantial and substantive changes","volume":"0","author":"Cohen","year":"2024","journal-title":"Mult Scler J"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2026.104058_bb0140","first-page":"S69","article-title":"What we learned from the history of multiple sclerosis measurement: expanded disability status scale","volume":"55","author":"\u00c7inar","year":"2018","journal-title":"Noro Psikiyatr Ars"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.clineuro.2010.03.022","article-title":"Role of MRI in diagnosis and treatment of multiple sclerosis","volume":"112","author":"Sahraian","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0150","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/ene.14432","article-title":"Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study","volume":"27","author":"Schriefer","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0155","article-title":"Heterogeneity in multiple sclerosis: scratching the surface of a complex disease","volume":"2011","author":"Disanto","year":"2010","journal-title":"Autoimmune Dis"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0160","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awz144","article-title":"Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines","volume":"142","author":"Filippi","year":"2019","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12883-023-03101-0","article-title":"The role of systemic \u0131mmune \u0131nflammatory \u0131ndex in showing active lesion \u0131n patients with multiple sclerosis\u202f: SII and other inflamatuar biomarker in radiological active multiple sclerosis patients","volume":"23","author":"Gokce","year":"2023","journal-title":"BMC Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102826","article-title":"Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"20","author":"Liu","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb0175","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u2018no evidence of disease activity\u2019 (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb0180","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104058_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.msard.2018.10.105","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Hauser","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0190","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"null","key":"10.1016\/j.autrev.2026.104058_bb0195","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/TCRM.S282390","article-title":"Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology","volume":"17","author":"Mancinelli","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.autrev.2026.104058_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"15_supplement","key":"10.1016\/j.autrev.2026.104058_bb0205","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1212\/WNL.94.15_supplement.2815","article-title":"Updated incidence of natalizumab-associated progressive multifocal leukoencephalopathy (PML) and its relationship with natalizumab exposure over time (2815)","volume":"94","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","article-title":"Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis","volume":"12","author":"Holm\u00f8y","year":"2019","journal-title":"BMC Res Notes"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0215","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40259-020-00414-1","article-title":"Haematopoietic stem cell transplantation for multiple sclerosis: current status","volume":"34","author":"Mariottini","year":"2020","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.autrev.2026.104058_bb0225","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/mja2.52578","article-title":"Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1","volume":"222","author":"Shipley","year":"2025","journal-title":"Med J Aust"},{"key":"10.1016\/j.autrev.2026.104058_bb0230","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5694\/mja2.52577","article-title":"Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2","volume":"222","author":"Shipley","year":"2025","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0235","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1212\/WNL.36.2.238","article-title":"High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations","volume":"36","author":"Durelli","year":"1986","journal-title":"Neurology"},{"issue":"9056","key":"10.1016\/j.autrev.2026.104058_bb0240","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0140-6736(96)06453-7","article-title":"Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis","volume":"349","author":"Barnes","year":"1997","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12883-015-0450-x","article-title":"Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses","volume":"15","author":"Caster","year":"2015","journal-title":"BMC Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0250","first-page":"199","article-title":"Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses","volume":"34","author":"La Mantia","year":"1994","journal-title":"Eur Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0255","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/WNL.39.7.969","article-title":"Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS","volume":"39","author":"Thompson","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2249.2002.01725.x","article-title":"Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects","volume":"127","author":"Mart\u00ednez-C\u00e1ceres","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clineuro.2013.12.021","article-title":"Mechanistic insights into corticosteroids in multiple sclerosis: war horse or chameleon?\u2606","volume":"119","author":"Krieger","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0270","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis","volume":"58","author":"Goodin","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104058_bb0275","unstructured":"Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000(4):Cd001331."},{"key":"10.1016\/j.autrev.2026.104058_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102401","article-title":"The effects of high-dose corticosteroids for multiple sclerosis relapse on blood pressure: a pilot study","volume":"45","author":"Tomkinson","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jns.2011.07.018","article-title":"Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis","volume":"309","author":"Vasheghani-Farahani","year":"2011","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0290","doi-asserted-by":"crossref","first-page":"071","DOI":"10.4274\/tnd.2019.75725","article-title":"The adverse effects of high-dose corticosteroids with early and late severe morbidity in the treatment of patients with multiple sclerosis: long-term observation results","volume":"25","author":"\u00d6merhoca","year":"2019","journal-title":"Turk J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0295","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2377-13-119","article-title":"The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry","volume":"13","author":"Nickerson","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0300","article-title":"An \u201cOutside-In\u201d and \u201cInside-Out\u201d consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases","volume":"14","author":"Morgan","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0305","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11910-021-01110-5","article-title":"Chronic demyelination and axonal degeneration in multiple sclerosis: pathogenesis and therapeutic implications","volume":"21","author":"Simkins","year":"2021","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"10.1016\/j.autrev.2026.104058_bb0310","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00018-022-04428-6","article-title":"Human myelin proteolipid protein structure and lipid bilayer stacking","volume":"79","author":"Ruskamo","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0315","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/122.12.2279","article-title":"A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: a study of 113 cases","volume":"122","author":"Lucchinetti","year":"1999","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-017-0428-6","article-title":"Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination","volume":"5","author":"Liu","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0325","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2249.2004.02646.x","article-title":"Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats","volume":"138","author":"Morgan","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00401-006-0083-7","article-title":"Chemokine expression by astrocytes plays a role in microglia\/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis","volume":"112","author":"Tanuma","year":"2006","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.autrev.2026.104058_bb0335","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/01.jnen.0000173893.01929.fc","article-title":"Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions","volume":"64","author":"Ambrosini","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0340","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/cells13121024","article-title":"Oligodendrocyte progenitors in glial scar: a bet on remyelination","volume":"13","author":"Marangon","year":"2024","journal-title":"Cells"},{"issue":"28","key":"10.1016\/j.autrev.2026.104058_bb0345","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1523\/JNEUROSCI.1709-08.2008","article-title":"STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury","volume":"28","author":"Herrmann","year":"2008","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0350","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/glia.23556","article-title":"The formation of a glial scar does not prohibit remyelination in an animal model of multiple sclerosis","volume":"67","author":"Haindl","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.autrev.2026.104058_bb0355","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-immunol-051116-052358","article-title":"Microglia function in the central nervous system during health and neurodegeneration","volume":"35","author":"Colonna","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0360","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-016-1653-y","article-title":"An updated histological classification system for multiple sclerosis lesions","volume":"133","author":"Kuhlmann","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0365","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41467-024-46068-3","article-title":"Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation","volume":"15","author":"van den Bosch","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104058_bb0370","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1742-2094-11-64","article-title":"Enhanced uptake of multiple sclerosis-derived myelin by THP-1 macrophages and primary human microglia","volume":"11","author":"Hendrickx","year":"2014","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0375","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jnr.490380409","article-title":"Activation of adult human derived microglia by myelin phagocytosis in vitro","volume":"38","author":"Williams","year":"1994","journal-title":"J Neurosci Res"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0380","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/1673-5374.290881","article-title":"Microglia in neurodegenerative diseases","volume":"16","author":"Xu","year":"2021","journal-title":"Neural Regen Res"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107921","article-title":"An early glycolysis burst in microglia regulates mitochondrial dysfunction in oligodendrocytes under neuroinflammation","volume":"26","author":"Suhail","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0390","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/NEN.0000000000000149","article-title":"Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis","volume":"74","author":"Peferoen","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0395","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1186\/1742-2094-10-35","article-title":"Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status","volume":"10","author":"Vogel","year":"2013","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0400","article-title":"A richer and more diverse future for microglia phenotypes","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"8","key":"10.1016\/j.autrev.2026.104058_bb0405","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nn.4338","article-title":"A polarizing question: do M1 and M2 microglia exist?","volume":"19","author":"Ransohoff","year":"2016","journal-title":"Nat Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0410","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-5728(93)90053-2","article-title":"Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level","volume":"48","author":"Bauer","year":"1993","journal-title":"J Neuroimmunol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0415","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.154.2.944","article-title":"TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines","volume":"154","author":"Renno","year":"1995","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0420","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1352458513498128","article-title":"Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration","volume":"20","author":"Rossi","year":"2014","journal-title":"Mult Scler J"},{"key":"10.1016\/j.autrev.2026.104058_bb0425","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1750-1326-9-56","article-title":"Interleukin-1\u03b2 causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53","volume":"9","author":"Rossi","year":"2014","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jneuroim.2014.02.014","article-title":"Cerebrospinal fluid IL-1&#x3b2; correlates with cortical pathology load in multiple sclerosis at clinical onset","volume":"270","author":"Seppi","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/cells10113163","article-title":"BASHY dye platform enables the fluorescence bioimaging of myelin debris phagocytosis by microglia during demyelination","volume":"10","author":"Pinto","year":"2021","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0440","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.20141656","article-title":"Inefficient clearance of myelin debris by microglia impairs remyelinating processes","volume":"212","author":"Lampron","year":"2015","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0445","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00401-020-02193-z","article-title":"TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis","volume":"140","author":"Cignarella","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0450","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.expneurol.2009.04.024","article-title":"Protective effects of microglia in multiple sclerosis","volume":"225","author":"Napoli","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0455","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fncel.2018.00178","article-title":"mCSF-Induced Microglial Activation Prevents Myelin Loss and Promotes Its Repair in a Mouse Model of Multiple Sclerosis","volume":"12","author":"Laflamme","year":"2018","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0460","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1189\/jlb.3RU0316-144R","article-title":"Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage","volume":"100","author":"Ushach","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0465","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp-2017-316011","article-title":"Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier","volume":"89","author":"Spencer","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0470","first-page":"319","article-title":"Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood\u2013brain barrier leakage and active demyelination","volume":"201","author":"Kirk","year":"2003","journal-title":"J Pathol J Pathol Soc Great Britain Ireland"},{"key":"10.1016\/j.autrev.2026.104058_bb0475","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2019.04.011","article-title":"IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis","volume":"332","author":"Setiadi","year":"2019","journal-title":"J Neuroimmunol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0480","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1093\/brain\/awac019","article-title":"Intrinsic blood-brain barrier dysfunction contributes to multiple sclerosis pathogenesis","volume":"145","author":"Nishihara","year":"2022","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0485","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nm1352","article-title":"Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity","volume":"12","author":"Chan","year":"2006","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb0490","article-title":"The interaction of innate immune and adaptive immune system","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm (2020)"},{"issue":"14","key":"10.1016\/j.autrev.2026.104058_bb0495","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1042\/CS20180548","article-title":"Adaptive innate immunity or innate adaptive immunity?","volume":"133","author":"\u010cern\u00fd","year":"2019","journal-title":"Clin Sci"},{"issue":"23","key":"10.1016\/j.autrev.2026.104058_bb0500","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1016\/j.febslet.2011.08.004","article-title":"The molecular basis of neurodegeneration in multiple sclerosis","volume":"585","author":"Lassmann","year":"2011","journal-title":"FEBS Lett"},{"key":"10.1016\/j.autrev.2026.104058_bb0505","article-title":"Autoreactive lymphocytes in multiple sclerosis: pathogenesis and treatment target","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0510","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0515","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ncrna.2021.12.002","article-title":"Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis","volume":"6","author":"Elkhodiry","year":"2021","journal-title":"Noncoding RNA Res"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0520","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/01616412.2017.1398371","article-title":"Role of perforin secretion from CD8+ T-cells in neuronal cytotoxicity in multiple sclerosis","volume":"40","author":"Zhao","year":"2018","journal-title":"Neurol Res"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0525","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0166-2236(02)02154-9","article-title":"Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases","volume":"25","author":"Neumann","year":"2002","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0530","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.181.3.1617","article-title":"Cutting edge: multiple sclerosis-like lesions induced by effector CD8 T cells recognizing a sequestered antigen on oligodendrocytes","volume":"181","author":"Saxena","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0535","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/ni.2015","article-title":"Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk","volume":"12","author":"Liu","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008808","article-title":"MHC class II molecules enhance Toll-like receptor mediated innate immune responses","volume":"5","author":"Frei","year":"2010","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0545","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000656","article-title":"Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15","volume":"7","author":"Enz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0550","doi-asserted-by":"crossref","DOI":"10.1177\/2055217320908046","article-title":"HLA-DRB1 allele impact on pediatric multiple sclerosis in a Hellenic cohort","volume":"6","author":"Gontika","year":"2020","journal-title":"Multiple Sclerosis J Exp Transl Clin"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0555","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/pgs.16.2","article-title":"HLA genes as modifiers of response to IFN-\u03b2-1a therapy in relapsing-remitting multiple sclerosis","volume":"17","author":"Mazdeh","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2026.104058_bb0560","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3389\/fimmu.2017.01781","article-title":"Granulocytes: new members of the antigen-presenting cell family","volume":"8","author":"Lin","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0565","doi-asserted-by":"crossref","first-page":"22357","DOI":"10.1038\/s41598-021-01942-8","article-title":"White blood cell count profiles in multiple sclerosis during attacks before the initiation of acute and chronic treatments","volume":"11","author":"Akaishi","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0570","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/sji.12147","article-title":"IL-17 and glutamate excitotoxicity in the pathogenesis of multiple sclerosis","volume":"79","author":"Kostic","year":"2014","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0575","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/jnc.13426","article-title":"Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity","volume":"136","author":"Zhang","year":"2016","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0580","doi-asserted-by":"crossref","first-page":"H558","DOI":"10.1152\/ajpheart.01275.2004","article-title":"Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia","volume":"289","author":"Gidday","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0585","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/jcm7120511","article-title":"The emerging role of neutrophil granulocytes in multiple sclerosis","volume":"7","author":"Woodberry","year":"2018","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104058_bb0590","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jneuroim.2011.11.009","article-title":"Neutrophils in multiple sclerosis are characterized by a primed phenotype","volume":"242","author":"Naegele","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0595","unstructured":"Espinoza VE, Emmady PD. Histology, Monocytes. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.; 2023."},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0600","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176460","article-title":"Phenotype, function, and differentiation potential of human monocyte subsets","volume":"12","author":"Boyette","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2026.104058_bb0610","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fimmu.2019.01642","article-title":"The ontogeny of monocyte subsets","volume":"10","author":"Wolf","year":"2019","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb0615","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnen\/nlab083","article-title":"Multiple sclerosis: microglia, monocytes, and macrophage-mediated demyelination","volume":"80","author":"Prineas","year":"2021","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0620","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1046\/j.1365-2567.1998.00473.x","article-title":"The effects of monocytes on the transendothelial migration of T lymphocytes","volume":"94","author":"Lidington","year":"1998","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0625","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archneur.59.3.391","article-title":"Migration of multiple sclerosis lymphocytes through brain endothelium","volume":"59","author":"Prat","year":"2002","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0630","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0165-5728(98)00002-2","article-title":"MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study","volume":"86","author":"McManus","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"Pt B","key":"10.1016\/j.autrev.2026.104058_bb0635","article-title":"MCP-1: function, regulation, and involvement in disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"Pt 12","key":"10.1016\/j.autrev.2026.104058_bb0640","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/brain\/awg285","article-title":"Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis","volume":"126","author":"Bar-Or","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104058_bb0645","first-page":"1","article-title":"High frequency of circulating non-classical monocytes is associated with stable remission in relapsing-remitting multiple sclerosis","author":"Minote","year":"2024","journal-title":"Immunol Med"},{"key":"10.1016\/j.autrev.2026.104058_bb0650","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2020.00594","article-title":"Expansion of neutrophils and classical and nonclassical monocytes as a hallmark in relapsing-remitting multiple sclerosis","volume":"11","author":"Haschka","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577433","article-title":"Alterations in peripheral blood monocyte and dendritic cell subset homeostasis in relapsing-remitting multiple sclerosis patients","volume":"350","author":"Monteiro","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0660","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4049\/jimmunol.1300040","article-title":"Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation","volume":"191","author":"Garcia","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0665","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1742-2094-9-215","article-title":"Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis","volume":"9","author":"Romme Christensen","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0670","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nri3671","article-title":"Monocytes and macrophages: developmental pathways and tissue homeostasis","volume":"14","author":"Ginhoux","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0675","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/cells8060543","article-title":"Nanomodulation of macrophages in multiple sclerosis","volume":"8","author":"Nally","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2026.104058_bb0680","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-01899-x","article-title":"CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation","volume":"17","author":"Grajchen","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0685","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0690","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.410190610","article-title":"Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions","volume":"19","author":"Hauser","year":"1986","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0695","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200100","article-title":"Increased NLRP3 inflammasome activation and pyroptosis in patients with multiple sclerosis with fingolimod treatment failure","volume":"10","author":"Malhotra","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0700","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/iji.12401","article-title":"Association of nod-like receptor protein-3 single nucleotide gene polymorphisms and expression with the susceptibility to relapsing-remitting multiple sclerosis","volume":"45","author":"Imani","year":"2018","journal-title":"Int J Immunogenet"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0705","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s12035-016-9864-8","article-title":"The Effects of IFN-\u03b2 1a on the expression of inflammasomes and apoptosis-associated speck-like proteins in multiple sclerosis patients","volume":"54","author":"Noroozi","year":"2017","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0710","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/brain\/awu388","article-title":"NLRP3 inflammasome is associated with the response to IFN-\u03b2 in patients with multiple sclerosis","volume":"138","author":"Malhotra","year":"2015","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0715","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/brain\/awaa084","article-title":"NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients","volume":"143","author":"Malhotra","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2026.104058_bb0720","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4274\/tji.galenos.2024.40427","article-title":"Birsen Elibol, Zehra Cemre Karakayal\u0131, \u015eule Terzio\u011flu U\u015fak, Azize Esra G\u00fcrsoy. Evaluation of inflammation-related proteins in multiple sclerosis disease with relapses and remissions","author":"Nisa Hocao\u011flu","year":"2024","journal-title":"Turk J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0725","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.4049\/jimmunol.1002720","article-title":"Differential expression of NLRP3 among hematopoietic cells","volume":"186","author":"Guarda","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0730","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molimm.2016.11.010","article-title":"Complement in the fundamental processes of the cell","volume":"84","author":"Hawksworth","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0735","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/2051-5960-2-53","article-title":"Complement activation in multiple sclerosis plaques: an immunohistochemical analysis","volume":"2","author":"Ingram","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.autrev.2026.104058_bb0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577147","article-title":"Complement activation in cerebrospinal fluid in clinically isolated syndrome and early stages of relapsing remitting multiple sclerosis","volume":"340","author":"H\u00e5kansson","year":"2020","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0745","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11064-025-04529-1","article-title":"Dual targeting of TLR9 and cGAS-STING pathways attenuates astrocyte inflammatory activation: potential implication in multiple sclerosis","volume":"50","author":"Shao","year":"2025","journal-title":"Neurochem Res"},{"issue":"15","key":"10.1016\/j.autrev.2026.104058_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.05.031","article-title":"STING orchestrates the neuronal inflammatory stress response in multiple sclerosis","volume":"187","author":"Woo","year":"2024","journal-title":"Cell"},{"issue":"9157","key":"10.1016\/j.autrev.2026.104058_bb0755","first-page":"964","article-title":"Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis","volume":"353","author":"Kappos","year":"1999","journal-title":"Gadolinium MRI Meta Anal. Group Lancet"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0760","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","article-title":"Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis","volume":"79","author":"Cagol","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb0770","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2023-331051","article-title":"Association of serum neurofilament light with microglial activation in multiple sclerosis","volume":"94","author":"Saraste","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0775","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","article-title":"Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS","volume":"61","author":"Malmestr\u00f6m","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0780","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000422","article-title":"Neurofilament light chain predicts disease activity in relapsing-remitting MS","volume":"5","author":"Varhaug","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb0785","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0790","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/jnc.13881","article-title":"Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis","volume":"141","author":"Novakova","year":"2017","journal-title":"J Neurochem"},{"key":"10.1016\/j.autrev.2026.104058_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103535","article-title":"High or increasing serum NfL is predictive of impending multiple sclerosis relapses","volume":"59","author":"Thebault","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"24","key":"10.1016\/j.autrev.2026.104058_bb0800","doi-asserted-by":"crossref","first-page":"25729","DOI":"10.18632\/aging.203790","article-title":"Factors influencing serum neurofilament light chain levels in normal aging","volume":"13","author":"Koini","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb0805","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1002\/acn3.51234","article-title":"Blood neurofilament light: a critical review of its application to neurologic disease","volume":"7","author":"Barro","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0810","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/EB.S139417","article-title":"Retinal imaging with optical coherence tomography: a biomarker in multiple sclerosis?","volume":"10","author":"Costello","year":"2018","journal-title":"Eye Brain"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0815","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31827b1a1c","article-title":"Active MS is associated with accelerated retinal ganglion cell\/inner plexiform layer thinning","volume":"80","author":"Ratchford","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0820","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.1993.tb05508.x","article-title":"Cytokine production by peripheral blood monocytes\/macrophages in multiple sclerosis patients","volume":"87","author":"Imamura","year":"1993","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb0825","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585231188625","article-title":"Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light","volume":"29","author":"Wessels","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2026.104058_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103922","article-title":"Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL","volume":"63","author":"Gawde","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0835","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12974-017-1034-z","article-title":"Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis","volume":"14","author":"Beaino","year":"2017","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0840","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0304-3940(95)12173-0","article-title":"Matrix metalloproteinases degrade myelin basic protein","volume":"201","author":"Chandler","year":"1995","journal-title":"Neurosci Lett"},{"issue":"14","key":"10.1016\/j.autrev.2026.104058_bb0845","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111804119","article-title":"CSF-1 maintains pathogenic but not homeostatic myeloid cells in the central nervous system during autoimmune neuroinflammation","volume":"119","author":"Hwang","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2026.104058_bb0850","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Olarte S, Bola\u00f1os NI, Echeverry M, Rodr\u00edguez AN, Cu\u00e9llar A, Puerta CJ, et al. Intermediate monocytes and cytokine production associated with severe forms of chagas disease. Front Immunol 2019;Volume 10 - 2019.","DOI":"10.3389\/fimmu.2019.01671"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0855","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.1992.00530270079022","article-title":"Cytokine secretion by multiple sclerosis monocytes: relationship to disease activity","volume":"49","author":"Rudick","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0860","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jneuroim.2018.03.016","article-title":"Peripheral blood monocyte count at onset may affect the prognosis in multiple sclerosis","volume":"319","author":"Akaishi","year":"2018","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0865","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41590-020-0661-1","article-title":"Cxcl10+ monocytes define a pathogenic subset in the central nervous system during autoimmune neuroinflammation","volume":"21","author":"Giladi","year":"2020","journal-title":"Nat Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0870","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-0039.2011.01780.x","article-title":"The human P2X7 receptor and its role in innate immunity","volume":"78","author":"Wiley","year":"2011","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.autrev.2026.104058_bb0875","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2X7 receptor: a main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb0880","doi-asserted-by":"crossref","first-page":"C1189","DOI":"10.1152\/ajpcell.2000.279.4.C1189","article-title":"Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors","volume":"279","author":"Gu","year":"2000","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.autrev.2026.104058_bb0885","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/ncomms10555","article-title":"Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1\u03b2 secretion in response to ATP","volume":"7","author":"Karmakar","year":"2016","journal-title":"Nat Commun"},{"issue":"35","key":"10.1016\/j.autrev.2026.104058_bb0890","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2026.104058_bb0895","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3389\/fimmu.2019.00793","article-title":"The P2X7 receptor is shed into circulation: correlation with c-reactive protein levels","volume":"10","author":"Giuliani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0900","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.894470","article-title":"Soluble P2X7 receptor is elevated in the plasma of COVID-19 patients and correlates with disease severity","volume":"13","author":"Garc\u00eda-Villalba","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0905","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","article-title":"Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker","volume":"38","author":"Yang","year":"2015","journal-title":"Trends Neurosci"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0910","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0915","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0920","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis","volume":"258","author":"Axelsson","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104854","article-title":"NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis","volume":"77","author":"Ammitzb\u00f8ll","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0930","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb0935","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1177\/13524585221094224","article-title":"Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis","volume":"28","author":"Pauwels","year":"2022","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.autrev.2026.104058_bb0940","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/jcb.23113","article-title":"Differential expression of complement proteins in cerebrospinal fluid from active multiple sclerosis patients","volume":"112","author":"Li","year":"2011","journal-title":"J Cell Biochem"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb0945","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.3390\/ijms13067676","article-title":"Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis","volume":"13","author":"F\u00fcvesi","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0950","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2009.10.019","article-title":"Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis","volume":"218","author":"Sawai","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2026.104058_bb0955","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.970486","article-title":"The role of the complement system in Multiple Sclerosis: a review","volume":"13","author":"Saez-Calveras","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0960","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/br.2016.668","article-title":"Proteomic analysis of cerebrospinal fluid for relapsing-remitting multiple sclerosis and clinically isolated syndrome","volume":"5","author":"Pavelek","year":"2016","journal-title":"Biomed Rep"},{"issue":"23","key":"10.1016\/j.autrev.2026.104058_bb0965","doi-asserted-by":"crossref","first-page":"12952","DOI":"10.1073\/pnas.1912839117","article-title":"Inflammation-related plasma and CSF biomarkers for multiple sclerosis","volume":"117","author":"Huang","year":"2020","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb0970","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2012.01.022","article-title":"Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier","volume":"148","author":"Arima","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2026.104058_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173127","article-title":"A comprehensive review of non-coding RNAs functions in multiple sclerosis","volume":"879","author":"Ghafouri-Fard","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0980","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ana.23967","article-title":"miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization","volume":"74","author":"Moore","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb0985","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1038\/s41598-020-63282-3","article-title":"Immune and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients","volume":"10","author":"Amoruso","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb0990","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.24931","article-title":"Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis","volume":"81","author":"Selmaj","year":"2017","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb0995","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.gene.2014.04.069","article-title":"miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis","volume":"544","author":"Honardoost","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.autrev.2026.104058_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104611","article-title":"Clinical outcomes and prognostic factors in patients with optic neuritis related to NMOSD and MOGAD in distinct ethnic groups from Latin America","volume":"72","author":"Carnero Contentti","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb1005","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S1474-4422(22)00200-9","article-title":"Diagnosis and classification of optic neuritis","volume":"21","author":"Petzold","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1134\/S1819712410010101","article-title":"Neuroinflammation biomarkers","volume":"4","author":"Piskunov","year":"2010","journal-title":"Neurochem J"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb1015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-008-1002-8","article-title":"A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis","volume":"255","author":"Weiner","year":"2008","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb1025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","article-title":"Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update","volume":"22","author":"Filipi","year":"2020","journal-title":"Int J MS Care"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2026.104058_bb1030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-5728(93)90244-S","article-title":"Interferon \u03b2 decreases T cell activation and interferon \u03b3 production in multiple sclerosis","volume":"46","author":"Noronha","year":"1993","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-5728(95)00072-A","article-title":"Interferon \u03b2-lb reduces Interferon \u03b3-induced antigen-presenting capacity of human glial and B cells","volume":"61","author":"Jiang","year":"1995","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1040","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(00)00403-3","article-title":"Immunomodulatory effects of interferon beta-1a in multiple sclerosis","volume":"112","author":"Liu","year":"2001","journal-title":"J Neuroimmunol"},{"issue":"null","key":"10.1016\/j.autrev.2026.104058_bb1045","first-page":"1123","article-title":"Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing\u2013remitting multiple sclerosis treatment","volume":"8","author":"Caporro","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb1050","article-title":"EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS","volume":"7","author":"Guerrera","year":"2020","journal-title":"Neurology Neuroimmunology &amp; Neuroinflammation"},{"issue":"8","key":"10.1016\/j.autrev.2026.104058_bb1055","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nm1620","article-title":"Type II monocytes modulate T cell\u2013mediated central nervous system autoimmune disease","volume":"13","author":"Weber","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1060","first-page":"115","article-title":"Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: a systematic review of case reports","volume":"22","author":"Rastkar","year":"2023","journal-title":"Curr J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb1065","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2174\/1570159X14666161208151525","article-title":"From leflunomide to teriflunomide: drug development and immunosuppressive oral drugs in the treatment of multiple sclerosis","volume":"15","author":"Aly","year":"2017","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb1070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2026.104058_bb1075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730342","article-title":"Teriflunomide treatment of multiple sclerosis selectively modulates CD8 memory T cells","volume":"12","author":"Tilly","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb1080","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419835077","article-title":"Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study","volume":"12","author":"Kallmann","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.autrev.2026.104058_bb1085","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11910-013-0394-8","article-title":"Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects","volume":"13","author":"Linker","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2026.104058_bb1090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2017.09.009","article-title":"Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis","volume":"86","author":"Diebold","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104058_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101451","article-title":"Dimethyl fumarate therapy reduces memory T cells and the CNS migration potential in patients with multiple sclerosis","volume":"37","author":"Holm Hansen","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104058_bb1100","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420915005","article-title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE","volume":"13","author":"Gold","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb1105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb1110","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.4049\/jimmunol.160.10.5037","article-title":"FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing","volume":"160","author":"Chiba","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104058_bb1115","article-title":"Different doses of fingolimod in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Wu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb1120","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/jnnp-2017-317411","article-title":"Cladribine: mechanisms and mysteries in multiple sclerosis","volume":"89","author":"Jacobs","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2026.104058_bb1125","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110304","article-title":"CLADIN- CLADribine and INnate immune response in multiple sclerosis \u2013 a phase IV prospective study","volume":"265","author":"Monif","year":"2024","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb1130","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","volume":"265","author":"Ceronie","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2026.104058_bb1135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.msard.2018.11.021","article-title":"Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis","volume":"29","author":"Cook","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb1140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1083\/jcb.201207175","article-title":"The discovery of natalizumab, a potent therapeutic for multiple sclerosis","volume":"199","author":"Steinman","year":"2012","journal-title":"J Cell Biol"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb1145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb1150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"St\u00fcve","year":"2006","journal-title":"Arch Neurol"},{"issue":"14","key":"10.1016\/j.autrev.2026.104058_bb1155","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult Scler J"},{"issue":"28","key":"10.1016\/j.autrev.2026.104058_bb1160","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011507","article-title":"Clinical adverse effects of natalizumab: protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"9805","key":"10.1016\/j.autrev.2026.104058_bb1165","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.autrev.2026.104058_bb1170","author":"Meligo"},{"key":"10.1016\/j.autrev.2026.104058_bb1175","author":"Meglio"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb1185","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/antib9040058","article-title":"The role of complement in the mechanism of action of therapeutic anti-cancer mAbs","volume":"9","author":"Golay","year":"2020","journal-title":"Antibodies"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb1190","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","article-title":"The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment","volume":"12","author":"Hauser","year":"2023","journal-title":"Neurol Ther"},{"issue":"10","key":"10.1016\/j.autrev.2026.104058_bb1195","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/13524585221079731","article-title":"Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5years","volume":"28","author":"Hauser","year":"2022","journal-title":"Mult Scler J"},{"issue":"6","key":"10.1016\/j.autrev.2026.104058_bb1200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039416","article-title":"Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis","volume":"7","author":"Rao","year":"2012","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1205","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/imm.12366","article-title":"Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis","volume":"144","author":"Wang","year":"2015","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2026.104058_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103891","article-title":"Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis","volume":"63","author":"Knudsen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2026.104058_bb1215","article-title":"Alemtuzumab for multiple sclerosis","volume":"6","author":"Riera","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb1220","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20041679","article-title":"Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients","volume":"201","author":"Muraro","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1042\/CS20140095","article-title":"Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis","volume":"128","author":"de Paula","year":"2015","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","article-title":"Autologous hematopoietic stem cell transplant in multiple sclerosis: recommendations of the national multiple sclerosis society","volume":"78","author":"Miller","year":"2021","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2026.104058_bb1235","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1212\/WNL.0000000000012449","article-title":"Autologous hematopoietic stem cell transplantation in active multiple sclerosis: a real-world case series","volume":"97","author":"Nicholas","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2026.104058_bb1240","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/B978-0-323-90242-7.00010-9","article-title":"Chapter 10 - early and late complications of hematopoietic stem cell transplantation","volume":"202","author":"Mikulska","year":"2024"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0165-5728(94)90075-2","article-title":"Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions","volume":"51","author":"B\u00f6","year":"1994","journal-title":"J Neuroimmunol"},{"issue":"5","key":"10.1016\/j.autrev.2026.104058_bb1250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb1255","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","article-title":"Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis","volume":"6","author":"Lucchinetti","year":"1996","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1260","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0165-5728(98)00031-9","article-title":"Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna","volume":"86","author":"Lassmann","year":"1998","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1265","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2990.2000.00217.x","article-title":"Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS","volume":"26","author":"van der Valk","year":"2000","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb1270","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4161\/org.25676","article-title":"Macrophages and CSF-1: implications for development and beyond","volume":"9","author":"Jones","year":"2013","journal-title":"Organogenesis"},{"issue":"3","key":"10.1016\/j.autrev.2026.104058_bb1275","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11011-020-00648-6","article-title":"A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis","volume":"36","author":"Ghafouri-Fard","year":"2021","journal-title":"Metab Brain Dis"},{"issue":"2","key":"10.1016\/j.autrev.2026.104058_bb1280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/1573406413666170906122803","article-title":"An update on the role of matrix metalloproteinases in the pathogenesis of multiple sclerosis","volume":"14","author":"Boziki","year":"2018","journal-title":"Med Chem"},{"issue":"4","key":"10.1016\/j.autrev.2026.104058_bb1285","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1084\/jem.20051342","article-title":"Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis","volume":"203","author":"Agrawal","year":"2006","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.autrev.2026.104058_bb1290","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1523\/JNEUROSCI.5512-08.2009","article-title":"The P2X7 receptor drives microglial activation and proliferation: a trophic role for P2X7R pore","volume":"29","author":"Monif","year":"2009","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2026.104058_bb1295","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12974-016-0621-8","article-title":"Interleukin-1\u03b2 has trophic effects in microglia and its release is mediated by P2X7R pore","volume":"13","author":"Monif","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"14","key":"10.1016\/j.autrev.2026.104058_bb1300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411624","article-title":"Neurofilament-light, a promising biomarker: analytical, metrological and clinical challenges","volume":"24","author":"Coppens","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"38","key":"10.1016\/j.autrev.2026.104058_bb1305","doi-asserted-by":"crossref","first-page":"15425","DOI":"10.1073\/pnas.1208031109","article-title":"Structural basis for activation of the complement system by component C4 cleavage","volume":"109","author":"Kidmose","year":"2012","journal-title":"Proc Natl Acad Sci"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226000728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:39:22Z","timestamp":1780097962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226000728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":261,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1568997226000728"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104058","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innate immunity and biomarkers of multiple sclerosis relapse versus remission","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104058"}}